Maria Rodriguez Aburto

Dr. Maria Rodriguez Aburto


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2024 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
PDF file
MAMaria Rodriguez Aburto
Maria Rodriguez Aburto
JCJohn F Cryan
John F Cryan

24 August 2018 in Science
Verified
Journal Article
Closed access
PDF file
MSMarta Segarra
Marta Segarra
MAMaria Rodriguez Aburto
Maria Rodriguez Aburto
FCFlorian Cop
Florian Cop
CLCecília Llaó-Cid
Cecília Llaó-Cid
RHRicarda Härtl
Ricarda Härtl
AAAmparo Acker-Palmer
Amparo Acker-Palmer
Developing the bloodbrain barrier: During development, signals need to be dynamically integrated by endothelial cells, neurons, and glia to achieve functional neuro-glia-vascular units in the central nervous system. During cortical development, neuronal Dab1 and ApoER2 receptors respond to a guidance cue called reelin. Studying mice, Segarra et al. found that Dab1 and ApoER2 are also expressed in endothelial cells (see the Perspective by Thomas). The integration of reelin signaling in endothelial cells and neurons facilitates the communication between vessels, glia, and neurons that is necessary for the correct positioning of neurons during cortical development. This integration is also important for correct communication at the neurovascular unit required for blood-brain barrier integrity in the mature brain. Science , this issue p. eaao2861 ; see also p. 754

8 June 2024 in Gut
Verified
Journal Article
Open access
PDF file
Marietta IacucciMarietta Iacucci
Marietta Iacucci
Giovanni SantacroceGiovanni Santacroce
Giovanni Santacroce
SMSnehali Majumder
Snehali Majumder
JMJennifer Morael
Jennifer Morael
IZIrene Zammarchi
Irene Zammarchi
SGSubrata Ghosh
Subrata Ghosh
Mounting evidence underscores the pivotal role of the intestinal barrier and its convoluted network with diet and intestinal microbiome in the pathogenesis of inflammatory bowel disease (IBD) and colitis-associated colorectal cancer (CRC). Moreover, the bidirectional association of the intestinal barrier with the liver and brain, known as the gut-brain axis, plays a crucial role in developing complications, including extraintestinal manifestations of IBD and CRC metastasis. Consequently, barrier healing represents a crucial therapeutic target in these inflammatory-dependent disorders, with barrier assessment predicting disease outcomes, response to therapy and extraintestinal manifestations. New advanced technologies are revolutionising our understanding of the barrier paradigm, enabling the accurate assessment of the intestinal barrier and aiding in unravelling the complexity of the gut-brain axis. Cutting-edge endoscopic imaging techniques, such as ultra-high magnification endocytoscopy and probe-based confocal laser endomicroscopy, are new technologies allowing real-time exploration of the cellular intestinal barrier. Additionally, novel advanced spatial imaging technology platforms, including multispectral imaging, upconversion nanoparticles, digital spatial profiling, optical spectroscopy and mass cytometry, enable a deep and comprehensive assessment of the molecular and ultrastructural barrier. In this promising landscape, artificial intelligence plays a pivotal role in standardising and integrating these novel tools, thereby contributing to barrier assessment and prediction of outcomes. Looking ahead, this integrated and comprehensive approach holds the promise of uncovering new therapeutic targets, breaking the therapeutic ceiling in IBD. Novel molecules, dietary interventions and microbiome modulation strategies aim to restore, reinforce, or modulate the gut-brain axis. These advancements have the potential for transformative and personalised approaches to managing IBD.

23 November 2022 in iScience
Verified
Journal Article
Open access
EKEmily G. Knox
Emily G. Knox
MAMaria Rodriguez Aburto
Maria Rodriguez Aburto
CTCarmen Tessier
Carmen Tessier
JNJatin Nagpal
Jatin Nagpal
GCGerard Clarke
Gerard Clarke
JCJohn F Cryan
John F Cryan
The gut microbiota influences host brain function, but the underlying gut-brain axis connections and molecular processes remain unclear. One pathway along this bidirectional communication system involves circulating microbially derived metabolites, such as short-chain fatty acids (SCFAs), which include butyrate and propionate. Brain endothelium is the main interface of communication between circulating signals and the brain, and it constitutes the main component of the blood-brain barrier (BBB). Here, we used a well-established in vitro BBB model treated with physiologically relevant concentrations of butyrate and propionate with and without lipopolysaccharide (LPS) to examine the effects of SCFAs on the actin cytoskeleton and tight junction protein structure. Both SCFAs induced distinct alterations to filamentous actin directionality. SCFAs also increased tight junction protein spikes and protected from LPS-induced tight-junction mis-localization, improved BBB integrity, and modulated mitochondrial network dynamics. These findings identify the actin cytoskeletal dynamics as another target further illuminating how SCFAs can influence BBB physiology.

26 December 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
NRNathaniel L. Ritz
Nathaniel L. Ritz
MBMarta Brocka
Marta Brocka
MBMary I. Butler
Mary I. Butler
CCCaitlin S. M. Cowan
Caitlin S. M. Cowan
CBCamila Barrera-Bugueño
Camila Barrera-Bugueño
JCJohn F Cryan
John F Cryan
Social anxiety disorder (SAD) is a crippling psychiatric disorder characterized by intense fear or anxiety in social situations and their avoidance. However, the underlying biology of SAD is unclear and better treatments are needed. Recently, the gut microbiota has emerged as a key regulator of both brain and behaviour, especially those related to social function. Moreover, increasing data supports a role for immune function and oxytocin signalling in social responses. To investigate whether the gut microbiota plays a causal role in modulating behaviours relevant to SAD, we transplanted the microbiota from SAD patients, which was identified by 16S rRNA sequencing to be of a differential composition compared to healthy controls, to mice. Although the mice that received the SAD microbiota had normal behaviours across a battery of tests designed to assess depression and general anxiety-like behaviours, they had a specific heightened sensitivity to social fear, a model of SAD. This distinct heightened social fear response was coupled with changes in central and peripheral immune function and oxytocin expression in the bed nucleus of the stria terminalis. This work demonstrates an interkingdom basis for social fear responses and posits the microbiome as a potential therapeutic target for SAD.

29 July 2016 in Nature Communications
Verified
Journal Article
Open access
CDC. Depner
C. Depner
HBH. Zum Buttel
H. Zum Buttel
NBN. Böğürcü
N. Böğürcü
ACAngel M Cuesta
Angel M Cuesta
MAMaria Rodriguez Aburto
Maria Rodriguez Aburto
AAA. Acker-Palmer
A. Acker-Palmer
Diffuse invasion of the surrounding brain parenchyma is a major obstacle in the treatment of gliomas with various therapeutics, including anti-angiogenic agents. Here we identify the epi-/genetic and microenvironmental downregulation of ephrinB2 as a crucial step that promotes tumour invasion by abrogation of repulsive signals. We demonstrate that ephrinB2 is downregulated in human gliomas as a consequence of promoter hypermethylation and gene deletion. Consistently, genetic deletion of ephrinB2 in a murine high-grade glioma model increases invasion. Importantly, ephrinB2 gene silencing is complemented by a hypoxia-induced transcriptional repression. Mechanistically, hypoxia-inducible factor (HIF)-1α induces the EMT repressor ZEB2, which directly downregulates ephrinB2 through promoter binding to enhance tumour invasiveness. This mechanism is activated following anti-angiogenic treatment of gliomas and is efficiently blocked by disrupting ZEB2 activity. Taken together, our results identify ZEB2 as an attractive therapeutic target to inhibit tumour invasion and counteract tumour resistance mechanisms induced by anti-angiogenic treatment strategies.